For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Research and development | 1,545 | 6,914 | 9,583 | 17,872* |
| General and administrative | 5,208 | 4,801 | 5,016 | 6,275* |
| Restructuring and impairment charges | 612 | 0 | 0 | 368* |
| Total operating expenses | 7,365 | 11,715 | 14,599 | 24,514 |
| Loss from operations | -7,365 | -11,715 | -14,599 | -24,514* |
| Interest income | 609 | 1,026 | 1,197 | 2,116* |
| Gain on sale of nonfinancial asset | 1,000 | - | - | - |
| Other expenses | - | 538 | - | - |
| Interest expense | 0 | - | 302 | 398* |
| Net loss | -5,756 | -11,227 | -13,704 | -22,797 |
| Basic EPS | -0.78 | -1.53 | -1.87 | -3.13 |
| Diluted EPS | -0.78 | -1.53 | -1.87 | -3.13 |
| Basic Average Shares | 7,343,909 | 7,323,106 | 7,311,032 | 7,284,268 |
| Diluted Average Shares | 7,343,909 | 7,323,106 | 7,311,032 | 7,284,268 |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)